HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Platelet inhibition with cangrelor in patients undergoing PCI.

AbstractBACKGROUND:
Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an intravenous blocker of the adenosine diphosphate receptor P2Y(12). This agent might have a role in the treatment of patients who require rapid, predictable, and profound but reversible platelet inhibition.
METHODS:
We performed a large-scale international trial comparing cangrelor with 600 mg of oral clopidogrel administered before percutaneous coronary intervention (PCI) in patients with acute coronary syndromes. The primary efficacy end point was a composite of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours.
RESULTS:
We enrolled 8877 patients, and 8716 underwent PCI. At 48 hours, cangrelor was not superior to clopidogrel with respect to the primary composite end point, which occurred in 7.5% of patients in the cangrelor group and 7.1% of patients in the clopidogrel group (odds ratio, 1.05; 95% confidence interval [CI], 0.88 to 1.24; P=0.59). Likewise, cangrelor was not superior at 30 days. The rate of major bleeding (according to Acute Catheterization and Urgent Intervention Triage Strategy criteria) was higher with cangrelor, a difference that approached statistical significance (3.6% vs. 2.9%; odds ratio, 1.26; 95% CI, 0.99 to 1.60; P=0.06), but this was not the case with major bleeding (according to the Thrombolysis in Myocardial Infarction criteria) or severe or life-threatening bleeding (according to Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries criteria). A secondary exploratory end point of death from any cause, Q-wave myocardial infarction, or ischemia-driven revascularization showed a trend toward a reduction with cangrelor, but it was not significant (0.6% vs. 0.9%; odds ratio, 0.67; 95% CI, 0.39 to 1.14; P=0.14).
CONCLUSIONS:
Cangrelor, when administered intravenously 30 minutes before PCI and continued for 2 hours after PCI, was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours. (ClinicalTrials.gov number, NCT00305162.)
AuthorsRobert A Harrington, Gregg W Stone, Steven McNulty, Harvey D White, A Michael Lincoff, C Michael Gibson, Charles V Pollack Jr, Gilles Montalescot, Kenneth W Mahaffey, Neal S Kleiman, Shaun G Goodman, Maged Amine, Dominick J Angiolillo, Richard C Becker, Derek P Chew, William J French, Franz Leisch, Keyur H Parikh, Simona Skerjanec, Deepak L Bhatt
JournalThe New England journal of medicine (N Engl J Med) Vol. 361 Issue 24 Pg. 2318-29 (Dec 10 2009) ISSN: 1533-4406 [Electronic] United States
PMID19915221 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright2009 Massachusetts Medical Society
Chemical References
  • Platelet Aggregation Inhibitors
  • Adenosine Monophosphate
  • cangrelor
  • Clopidogrel
  • Ticlopidine
Topics
  • Acute Coronary Syndrome (drug therapy, mortality, therapy)
  • Adenosine Monophosphate (adverse effects, analogs & derivatives, therapeutic use)
  • Administration, Oral
  • Aged
  • Angioplasty, Balloon, Coronary
  • Clopidogrel
  • Combined Modality Therapy
  • Double-Blind Method
  • Female
  • Hemorrhage (chemically induced)
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Myocardial Infarction (prevention & control)
  • Platelet Aggregation Inhibitors (adverse effects, therapeutic use)
  • Retreatment
  • Ticlopidine (adverse effects, analogs & derivatives, therapeutic use)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: